
- Drug Topics September/October 2024
- Volume 168
- Issue 07
FDA Approves First-Ever OTC Hearing Aid Software
Over 30 million American adults experience some hearing loss, yet only one-fifth benefit from hearing aids; the FDA’s approval will expand access to the technology for the patient population.
The
“Hearing loss is a significant public health issue impacting millions of Americans,” said Michelle Tarver, MD, PhD, acting director of the FDA’s Center for Devices and Radiological Health, in the release.1 “Today’s marketing authorization of an OTC hearing aid software on a widely used consumer audio product is another step that advances the availability, accessibility and acceptability of hearing support for adults with perceived mild to moderate hearing loss.”
The HFA uses a self-fitting process that allows users to adjust settings without help from a hearing professional. Users’ hearing levels are assessed from the iOS HealthKit, and after initial setup, users can fine-tine volume, tone, and balance to meet their specific needs.
The FDA’s authorization is supported by a clinical study involving 118 subjects with perceived mild to moderate hearing loss at multiple US sites. The results demonstrated that participants who used the HAF self-fitting strategy achieved similar perceived benefit as participants who received professional fitting of the same device.1
Additionally, results demonstrated comparable performance for tests measuring levels of amplification in the ear canal and as a measure of speech understanding in noise.1 No adverse events related to the device were observed in the study.
The HAF was reviewed under the FDA’s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.
READ MORE:
Over 30 million American adults experience some hearing loss, yet only about one-fifth of those who could benefit from hearing aids seek help.2
Hearing loss can result from aging, exposure to loud noises, medical conditions, and other factors, and can negatively impact communication, relationships, work or school performance, and emotional well-being. Studies have shown that using hearing aids can reduce the frequency or severity of cognitive decline,
Congress passed bipartisan legislation in 2017 requiring the FDA to establish a category of OTC hearing aids, but full implementation didn’t occur until October 2022. Now, these regulations allow consumers with mild to moderate hearing loss to purchase hearing aids directly from stores or online retailers without needing a medical exam, prescription, or audiologist appointment.3 This represents a significant step towards ensuring greater access to safe and effective hearing aid options for the patient population.
The HAF will be able to be paired to iOS devices following a free software update, as revealed at Apple’s recent “Glow Up” event.4
READ MORE:
Are you ready to elevate your pharmacy practice? Sign up today for our
References
1. FDA authorizes first over-the-counter hearing aid software. News release. FDA. September 12, 2024. Accessed September 13, 2024. https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-over-counter-hearing-aid-software?utm_medium=email&utm_source=govdelivery
2. OTC hearing aids: What you should know. Fact sheet. FDA. Accessed September 13, 2024. https://www.fda.gov/medical-devices/hearing-aids/otc-hearing-aids-what-you-should-know
3. FDA finalizes historic rule enabling access to over-the-counter hearing aids for millions of Americans. News release. FDA. August 16, 2022. Accessed September 13, 2024. https://web.archive.org/web/20221028042729/https:/www.fda.gov/news-events/press-announcements/fda-finalizes-historic-rule-enabling-access-over-counter-hearing-aids-millions-americans
4. Aquino S. Apple’s ‘It’s Glowtime’ special event put an appreciably vivid glow on accessibility. Forbes. September 11, 2024. Accessed September 13, 2024. https://www.forbes.com/sites/stevenaquino/2024/09/11/apples-its-glowtime-special-event-put-an-appreciably-vivid-glow-on-accessibility/
Articles in this issue
about 1 year ago
FDA Approves Ceftobiprole Medocaril Sodium for 3 Indicationsabout 1 year ago
Supplement Snapshot: Vitamin D and Respiratory Tract Infectionsabout 1 year ago
The Perils of Frivolous Lawsuitsabout 1 year ago
OTC Product Roundup: Topical Analgesicsabout 1 year ago
Beyond Blood Glucose: Addressing Adolescent Diabetes ChallengesNewsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.